Faculty Interviews from the 29th Annual International Prostate Cancer Update

On The Role of Genotypic and Phenotypic Biomarkers in Prostate Cancer

David M. Albala, MD
Crouse Hospital and Associated Medical Professionals
Syracuse, NY, USA

On the Role of Axumin PET Scans in Patients with Biochemical Recurrent Prostate Cancer

Gerald L. Andriole, Jr., MD
Washington University
St. Louis, MO, USA

On Advanced Radiation Oncology Techniques in Prostate Cancer

Steven E. Finkelstein, MD
Advanced Urology Institute
Panama City, FL, USA

On the Optimal Application of PSA Testing

Richard G. Harris, MD
Chicago, IL, USA

On Risk-Stratifying Men for Prostate Cancer Early in Life

Karim Kader, MD, PhD
UC San Diego Health System
La Jolla, CA, USA

On the Interactions Between the AUA, CPT, and RUC

Ronald P. Kaufman, MD
Albany Medical College
Albany, NY, USA

On a High-Resolution Ultrasound Technology for Detecting Prostate Cancer

Laurence Klotz, MD
University of Toronto
Toronto, ON, Canada

On Abiraterone and Flare

Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, AZ, USA

On the Field of Theranositics and Radioligand Therapies

Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, AZ, USA

On Second Opinion Diagnosis in Prostate Pathology

Francisco G. La Rosa, MD
University of Colorado, Denver
Aurora, CO, USA

On the Current State of M0 Prostate Cancer

Neal D. Shore, MD
Carolina Urologic Research Center
Myrtle Beach, SC, USA

On the Future of Precision Diagnosis of Prostate Cancer

Faina Shtern, MD
AdMeTech Foundation
Boston, MA, USA

On the Possibility of 3D Mapping Biopsy Replacing MRI

Nelson N. Stone, MD
Mount Sinai School of Medicine
New York, NY, USA